BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Lymphoma, B-CellNon-Hodgkin's LymphomaLymphoma, Low-Grade
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 45
- Registration Number
- NCT00220285
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2012-11-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 432
- Registration Number
- NCT00206635
An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS
Phase 4
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: Betaferon/Betaseron
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 271
- Registration Number
- NCT00206648
Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes
Phase 4
Completed
- Conditions
- Hot Flashes
- Interventions
- Drug: Placebo transdermal
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-05-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 425
- Registration Number
- NCT00206622
Efficacy and Safety Study of an Oral Contraceptive in Healthy Females
Phase 3
Completed
- Conditions
- Contraception
- Interventions
- Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 499
- Registration Number
- NCT00206583
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
🇺🇸University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States
STEPS Trial - Spheramine Safety and Efficacy Study
Phase 2
Terminated
- Conditions
- Parkinson Disease
- Interventions
- Procedure: Placebo
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 71
- Registration Number
- NCT00206687
Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2010-04-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 71
- Registration Number
- NCT00185315
Efficacy and Safety of Testogel® in Men With Partial Androgen Deficiency of Aging Males (PADAM)
Phase 3
Completed
- Conditions
- Androgens (Deficiency)Male
- Interventions
- Drug: Testogel (Testosterone, BAYV001915)Drug: Placebo
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 363
- Registration Number
- NCT00185198
Study to Investigate the Efficacy of a Non-hormonal Drug Against Endometriosis Associated Pelvic Pain
Phase 2
Completed
- Conditions
- Endometriosis
- Interventions
- Drug: CCR1-Antagonist (BAY86-5047, ZK811752)Drug: Placebo
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2016-05-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 110
- Registration Number
- NCT00185341
FC Patch Comparator Study
Phase 3
Completed
- Conditions
- Contraception
- Interventions
- Drug: BAY86-5016, SH P00331FDrug: SH P00331N
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2015-12-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 422
- Registration Number
- NCT00185354
© Copyright 2025. All Rights Reserved by MedPath